Canada - English - Health Canada

novartis pharmaceuticals canada inc - secukinumab - solution - 300mg - secukinumab 300mg

Canada - English - Health Canada

novartis pharmaceuticals canada inc - secukinumab - solution - 300mg - secukinumab 300mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - secukinumab -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - secukinumab -

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - secukinumab 150mg;   - powder for injection - 150 mg - active: secukinumab 150mg   excipient: histidine hydrochloride monohydrate nitrogen polysorbate 80 sucrose - cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - secukinumab -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - secukinumab - solution for injection - 150mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - secukinumab - solution for injection - 150mg/1ml

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - secukinumab 150 mg/ml;   - solution for injection - 300 mg/2ml - active: secukinumab 150 mg/ml   excipient: histidine methionine nitrogen polysorbate 80 trehalose dihydrate water for injection - cosentyx is indicated for the treatment of adult patients with active ankylosing spondylitis.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - secukinumab 150 mg/ml;   - solution for injection - 300 mg/2ml - active: secukinumab 150 mg/ml   excipient: histidine methionine nitrogen polysorbate 80 trehalose dihydrate water for injection - cosentyx is indicated for the treatment of adult patients with active ankylosing spondylitis.